I-Corps: Development and Commercial Feasibility of a Microfluidic Drug Discovery Kit

I-Corps：微流控药物发现试剂盒的开发和商业可行性

• 批准号: 1355920
• 负责人: Siva Vanapalli
• 金额: $ 5万
• 依托单位: Texas Tech University
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-10-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1355920&HistoricalAwards=false
• 关键词: Corps; Development; Commercial; Feasibility; Microfluidic

The proposed innovation uses microfluidic technology to rapidly generate fluid mixtures of drugs with fine increments in their proportions to assist with combination drug development. Although automated pipetting systems and well plates have been the workhorse for primary drug screening where thousands of individual compounds are tested, few, if any, are flexible for screening combination drugs because of the complexity involved in scanning a large number of drug-and-dose combinations. This technology involves injecting plugs of drug solutions into a uniquely designed microfluidic device that allows autonomous mixing and dilution. This approach allows mixing drugs in very fine increments with significantly less consumption of drug samples and reagents. Development of a microfluidic drop technology for combination drug discovery may accelerate the process of drug screening and discovery of new or combination drugs. It would help to reduce the drug development time cycle and cost as it facilitates fluid mixtures of drugs in very small increments. Outside of the pharmaceutical industry, this technology could also play a role in combinational mixing of consumer products and biomaterials.

提出的创新使用微流体技术快速生成药物的流体混合物，其比例有细微的增量，以协助联合药物的开发。虽然自动移液系统和孔板已经成为初步药物筛选的主力，其中测试了数千种单独的化合物，但由于扫描大量药物和剂量组合的复杂性，很少有，如果有的话，是灵活的筛选联合药物的。这项技术包括将药物溶液注入一个独特设计的微流体装置，允许自动混合和稀释。这种方法允许以非常精细的增量混合药物，大大减少药物样品和试剂的消耗。微流控滴联合药物发现技术的发展可以加速药物筛选和新药物或联合药物的发现过程。这将有助于减少药物开发的时间周期和成本，因为它有利于以非常小的增量进行药物的液体混合。在制药行业之外，这项技术还可以在消费品和生物材料的组合混合中发挥作用。